Zai Refractory SCLC (Small Cell Lung Cancer) - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to find the safest and most effective dose of an experimental drug called ZL-1310 (the study drug). We want to know if this drug can be beneficial for people with small cell lung cancer (SCLC) that progressed after at least one round of chemotherapy.
Small Cell Lung Cancer (SCLC)
¿Quién puede participar en el Estudio?
Adults ages 18+ who:
- Are diagnosed with SCLC that did not respond to treatment
- Have received at least one line of chemotherapy
For more information about who can join this study, please contact the study team at annemarie.peters@duke.edu.
¿Qué Implica?
If you choose to join this study, you will get the study drug once every 3 weeks. The drug is given as an intravenous (IV) infusion. The study drug will be given at various doses during the study. Your dose of study drug will depend on when you join the study.
You will continue to receive the study drug for as long as the study doctor and you feel that you are getting a benefit.
Detalles del Estudio
